Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Gr 138950
2. Gr-138950
3. Gr138950
4. Gr138950c
5. Sapri-sartan Potassium
6. Saprisartan Potassium
1. 146623-69-0
2. Gr-138950
3. Gr 138950
4. 3-[[3-bromo-2-[2-(trifluoromethylsulfonylamino)phenyl]-1-benzofuran-5-yl]methyl]-5-cyclopropyl-2-ethylimidazole-4-carboxamide
5. Gr138950
6. Hs64ng1g69
7. Saprisartan [inn:ban]
8. Unii-hs64ng1g69
9. 3-((3-bromo-2-(2-(trifluoromethylsulfonylamino)phenyl)-1-benzofuran-5-yl)methyl)-5-cyclopropyl-2-ethylimidazole-4-carboxamide
10. Gr-138950x
11. Saprisartan [inn]
12. Saprisartan [who-dd]
13. Schembl120388
14. Chembl305544
15. Gtpl6899
16. Dtxsid00163422
17. Chebi:190069
18. Zinc3919581
19. Bdbm50469901
20. Db01347
21. L000533
22. Q20817193
23. 1-({3-bromo-2-[2-(trifluoromethane)sulfonamidophenyl]-1-benzofuran-5-yl}methyl)-4-cyclopropyl-2-ethyl-1h-imidazole-5-carboxamide
24. 1-[[3-bromo-2-[2-[[(trifluoromethyl)sulphonyl ]amino ]phenyl]-5-benzofuranyl]methyl]-4-cyclopropyl-2-ethyl-1h-imidazole-5-carboxamide
25. 1-[[3-bromo-2-[2-[[(trifluoromethyl)sulphonyl]amino]phenyl]-5-benzofuranyl]methyl]-4-cyclopropyl-2-ethyl-1h-imidazole-5-carboxamide
26. 1h-imidazole-5-carboxamide, 1-((3-bromo-2-(2-(((trifluoromethyl)sulfonyl)amino)phenyl)-5-benzofuranyl)methyl)-4-cyclopropyl-2-ethyl-
27. 3-[[3-bromo-2-[2-(triluoromethylsulonylamino)phenyl]-1-benzouran-5-yl]methyl]-5-cyclopropyl-2-ethylimidazole-4-carboxamide
| Molecular Weight | 611.4 g/mol |
|---|---|
| Molecular Formula | C25H22BrF3N4O4S |
| XLogP3 | 5.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 8 |
| Exact Mass | 610.04972 g/mol |
| Monoisotopic Mass | 610.04972 g/mol |
| Topological Polar Surface Area | 129 Ų |
| Heavy Atom Count | 38 |
| Formal Charge | 0 |
| Complexity | 979 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Saprisartan is used in the treatment of hypertension and heart failure.
By inhibiting the angiotensin II receptor, this drug leades to a decrease in sodium reabsorption and a decrease in vasoconstriction. This has the combined effect of decreasing blood pressure.
Angiotensin II Type 1 Receptor Blockers
Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS. (See all compounds classified as Angiotensin II Type 1 Receptor Blockers.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Saprisartan is a selective, potent, orally active and long-acting nonpeptide Angiotensin II type 1 (AT1) receptor antagonist. Saprisartan blocks the renin-angiotensin-aldosterone system (RAAS) at the level of the AT1 receptor that mediates most, if not all, of the important actions of Ang II. Saprisartan binds reversibly to the AT1 receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. AT1 receptor antagonists avoid the nonspecificity of the Ang I converting enzyme (ACE) inhibitors.
ABOUT THIS PAGE
19
PharmaCompass offers a list of Saprisartan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Saprisartan manufacturer or Saprisartan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Saprisartan manufacturer or Saprisartan supplier.
PharmaCompass also assists you with knowing the Saprisartan API Price utilized in the formulation of products. Saprisartan API Price is not always fixed or binding as the Saprisartan Price is obtained through a variety of data sources. The Saprisartan Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Saprisartan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Saprisartan, including repackagers and relabelers. The FDA regulates Saprisartan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Saprisartan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Saprisartan supplier is an individual or a company that provides Saprisartan active pharmaceutical ingredient (API) or Saprisartan finished formulations upon request. The Saprisartan suppliers may include Saprisartan API manufacturers, exporters, distributors and traders.
Saprisartan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Saprisartan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Saprisartan GMP manufacturer or Saprisartan GMP API supplier for your needs.
A Saprisartan CoA (Certificate of Analysis) is a formal document that attests to Saprisartan's compliance with Saprisartan specifications and serves as a tool for batch-level quality control.
Saprisartan CoA mostly includes findings from lab analyses of a specific batch. For each Saprisartan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Saprisartan may be tested according to a variety of international standards, such as European Pharmacopoeia (Saprisartan EP), Saprisartan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Saprisartan USP).
